Everolimus
Everolimus inhibits mTOR, a signalling pathway involved in cell growth and immune activity. It is used in distinct specialist settings, including selected cancers and prevention of organ rejection.
Key points
- Oncology and transplant everolimus products can have different formulations, treatment goals and monitoring and should not be interchanged without specialist confirmation.
- Everolimus can suppress immunity and affect the lungs, mouth, blood counts, glucose, lipids, kidneys and wound healing.
- Fever, worsening cough, breathlessness or severe mouth sores needs prompt contact with the treating team.
Listings are for comparison and general information, not a cancer or transplant regimen; suitability and supply depend on specialist, clinician and pharmacy checks, formulation verification, monitoring and prescription requirements.
What everolimus is used for
Everolimus may be used for selected advanced cancers or tumours and in some transplant immunosuppression plans. The dose form, companion medicines and treatment target depend on the indication.
How everolimus works
Everolimus binds an intracellular protein and inhibits mTOR signalling. This can slow selected tumour-cell pathways or reduce immune activation, while also increasing infection and metabolic risks.
Important safety checks
Review includes infection and vaccination history, lung symptoms, liver or kidney function, blood counts, glucose, lipids, pregnancy and planned surgery. Strong enzyme inhibitors or inducers, including some antibiotics, antifungals, seizure medicines and herbal products, can substantially change exposure. Mouth care and wound-healing plans should follow the specialist team.
When to seek urgent care
Seek urgent advice for fever, shaking chills, new or worsening cough, breathlessness, chest pain, severe mouth ulceration, facial swelling, markedly reduced urine, unusual bleeding or a severe rash. Do not stop transplant everolimus without the transplant team.